Switching Therapies for Patients with HIV and History of Resistance

Opinion
Video

Experts on HIV offer insights into switching therapies for patients with a history of resistance, highlighting ways to simplify and optimize treatment.

BIC = bictegravir

DRV = darunavir

DTG = dolutegravir

F/TAF = FTC/TAF = Emtricitabine/Tenofovir alafenamide

F/TDF = FTC/TDF = Emtricitabine/Tenofovir disoproxil fumarate

B/F/TAF = BIC/FTC/TAF = Bictegravir/Emtricitabine/Tenofovir alafenamide (single tablet regimen)

DTG/ABC/3TC = Dolutegravir/Abacavir/Lamivudine (single tablet regimen)

DTG + F/TAF = DTG + FTC/TAF = Dolutegravir + Emtricitabine/Tenofovir alafenamide (multi-tablet regimen)

D/C/F/TAF = DRV/COBI/FTC/TAF = Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (single tablet regimen)

DTG/3TC = Dolutegravir/Lamivudine (single tablet regimen)

CAB = Cabotegravir

CAB + RPV = Cabotegravir + Rilpivirine

Video content above is prompted by the following questions:

  • Which tests do you order to test for resistance?
  • How does your approach differ with a patient who is on their first regimen vs. someone who’s on later lines of treatment?
Related Videos
A panel of 4 experts on asthma
A panel of 4 experts on asthma
4 KOLs are featured in this series
4 KOLs are featured in this series
Shauna Applin, ARNP, an expert on HIV
Shauna Applin, ARNP, an expert on HIV
3 KOLs are featured in this program.
3 KOLs are featured in this program.
A panel of 4 experts on HIV
A panel of 4 experts on asthma
© 2024 MJH Life Sciences

All rights reserved.